Latest Tax Rebates News

archTIS Limited reported a 12% increase in annual recurring revenue to $4 million and achieved net positive cash flow from operations, while signing a binding term sheet to acquire Direktiv’s assets, signaling strategic growth in data-centric security.

First Graphene Limited reports a robust December quarter with new patents, expanded distribution networks, and advancing commercial trials, positioning the company on a path to cash breakeven.

TrivarX has solidified its regulatory strategy for the pivotal MEB-001 trial with the FDA and unveiled a new algorithm that expands its mental health screening reach beyond sleep clinics.

Hamelin Gold's December 2024 quarterly report reveals a significant new gold mineralisation zone at the Jazz prospect in the Tanami Province, alongside ongoing exploration advances in the Yilgarn Province and a new tenement application for the Venus project.

West Cobar Metals reports significant resource expansions at its Salazar project alongside promising copper-antimony test results at Bulla Park, while aggressively trimming costs to extend its runway.

Echo IQ Limited has secured FDA clearance for its EchoSolv AS technology and appointed a US-based CEO, marking a pivotal shift towards commercialisation in the American healthcare market.

FBR Limited has successfully completed its US Demonstration Program with CRH Ventures, raising $8 million through a Share Purchase Plan and positioning itself for a significant joint venture in the US construction robotics market.

First Graphene has secured an additional AUD$404,300 R&D tax rebate for significant manufacturing process improvements at its Henderson facility, complementing a recent AUD$166,000 rebate from UK-based research efforts.

Energy Action Limited reports a strong positive operating cash flow of $1.08 million in Q2 FY25, boosted by customer receipts and an R&D tax rebate, while advancing its AI-driven energy platform Utilibox to fuel future growth.

Mont Royal Resources confirms a continuous lithium mineralised zone at its Bohier Lithium Project in Quebec, highlighting promising exploration potential while stepping back from its Wapatik Gold-Copper option.

PYC Therapeutics reports substantial progress across all four of its drug development programs in Q4 2024, including key regulatory designations and clinical milestones that set the stage for pivotal trials in 2025.

Noxopharm’s December 2024 quarterly report reveals expanding global interest in its Sofra technology through new Material Transfer Agreements and a strengthened cash position following a significant R&D tax rebate.